Enliven Therapeutics, Inc. (ELVN) — Form SCHEDULE 13G/A: Ownership over 5% (passive) (amendment)

About this filing

Enliven Therapeutics, Inc. (ELVN) filed Form SCHEDULE 13G/A (ownership over 5% (passive) (amendment)) with the SEC on Oct 27, 2026. A Schedule 13G reports a passive investor owning more than 5% of the company.